Brendan McIntyre

Aug 20, 2024 | nature.com | Guillem Pascual-Pasto |Kathrin Bernt |Adam J. Wolpaw |Dimiter S. Dimitrov |Brendan McIntyre |Anna M. Giudice

AbstractNovel chimeric antigen receptor (CAR) T-cell approaches are needed to improve therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid tumor that expresses cell-surface GPC2 and GD2 with a tumor microenvironment infiltrated by CD16a-expressing innate immune cells. Here we engineer T-cells to express a GPC2-directed CAR and simultaneously secrete a bispecific innate immune cell engager (BiCE) targeting both GD2 and CD16a.